Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


03. December 2020 | 11:51 CET

Bayer, Carnival, Silver Viper - Rough weather on the high seas!

  • Investments
Photo credits: Silver Viper Minerals

Gold up 60 Dollars! Precious metals are beginning to recover from their recent decline in the options market. It is often rumored that the sales in gold & silver have to do with raising money from the prominent market players. Short Gold - Long Nasdaq. The NDX, in any case, climbed to a new all-time high yesterday. In the face of renewed speculation frenzy, which also drove the Bitcoin price back to record highs, some financial media have revived the old argument. The Blockchain creature would be the new gold is the slogan, but some Tweets also show, e.g., from market analyst Fred Hickey, why Bitcoin should not be confused with the yellow metal: "The history of gold is 3,000 years old - that of Bitcoin not even 10 - and gold has a natural attraction!" Currently, the value ratio is 10:1 - Gold analysts see the price at over USD 20,000 in 2025, but Bitcoin already costs that today.

time to read: 4 minutes by André Will-Laudien


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Bayer - The naughty daughter

A federal judge has rejected Bayer AG's proposed USD 648 million settlement in a class-action lawsuit filed by cities and other plaintiffs alleging PCB contamination. In a decision issued on November 25, the US District Judge in Los Angeles said the agreement appeared "too broad in scope" because it could shield Bayer from future claims and would require the plaintiffs to indemnify Bayer against such claims. Bayer acquired Monsanto for USD 63 billion in 2018 and said in a statement that it would work with plaintiffs to resolve their concerns. Los Angeles County and the cities of San Diego, Baltimore and Portland are among the plaintiffs, who are now from 36 states. The payout was to include USD 550 million for Class Members and up to USD 98 million for attorneys' fees and disbursements. For the time being, the proceedings continue.

Already in June, Bayer announced plans to pay approximately USD12 billion to settle litigation relating to Monsanto's herbicide Roundup. Bayer has now stated that Roundup is safe and well-tolerated by humans. A further problem exists with polychlorinated biphenyls (PCBs). They were once used extensively to insulate electrical appliances and were also used in products such as carbonless paper, sealants, flooring and paints. The US government banned PCBs in 1979 after they were linked to cancer and other health problems. Monsanto produced PCBs from 1935 to 1977, and now the Company is trying to close the story once and for all.

Bayer is still swirling in the US wave of lawsuits, and in 2020, is one of the weakest stocks in the DAX. The Company has a market value of only about EUR 47 billion, at its height, it used to be over EUR 130 billion. When Bayer will be able to escape from the clutches of justice remains questionable. In any case, the Monsanto takeover will go down in the history books as one of the most significant value destructions of all time. For Bayer, this is a disservice done by a management team that is completely detached from the Company.

Carnival Corp. - Goodbye cruises

The recent explosion of coronavirus infections means the expectation that cruises will commence are premature. Carnival, together with Royal Caribbean and Norwegian Cruise Lines, is one of the big 3 players in this sector, which has been lying idle since the beginning of the year. The pre-sold cruises for February and March are cancelled again. One can now only hope for free travel in the summer.

The stocks of the badly shaken industry crashed again. Carnival's annual loss amounts to an impressive 60%. The share recovered by 60% from its November low, but the volatility demonstrates the pitfall of the percentage calculation. The long term investor is sitting on massive losses, the short term oriented and courageous speculator, armed with the hope of a vaccine, can calmly realize again and hope for the next sell-off of the stock. Fundamentally, all significant lines are already on the verge of over-indebtedness, and various government aid packages have been applied for.

Given the 99 percent drop in sales, the third quarter was an absolute catastrophe, and the figures for the fourth quarter could hardly be better. The fiscal year ended now on November 30, and Carnival will probably report the worst figures in its long history. However, the stock market threw out a lifebelt, as Carnival reported a sale of shares worth USD 1.5 billion on November 10. They took advantage of the rally after the US election, in which the shares rose from USD 14 to over USD 20.

The new money will now delay the risk of bankruptcy, but not for too long. Only on the assumption of rapid global approval of a vaccine and a quick market launch could the tide turn; otherwise, the pandemic will continue well into 2021. That may be too long for Carnival. Management sold shares yesterday after reaching a 6-month high.

Silver Viper - First-class projects, tax effects

"Tax Loss Selling" is the keyword of the last days. In the course of the somewhat lighter precious metal prices, many mines and explorers also went down. Canadian investors are taking advantage of the tax benefits to offset their annual profits with incurred losses, in turn creating liquidity resources for re-entry after the turn of the year. The promising Silver Viper also entered the correction mill with a 50 percent loss - but the projects are still 1A in character.

The former Pan American Silver project "La Virginia" not only has first-class historical exploration, but the drill bit has recently uncovered discoveries and great potential in new zones such as El Rubi. The gold-silver project is located in northern Sonora, the leading gold-producing state of Mexico.

With a total of 188 drill holes and peak values of 7.63 grams of gold and 363 grams of silver per tonne, the area is truly inspiring as the structures are relatively near surface. Much of the project has not yet been mapped or drilled, which certainly offers some surprises. As of September 30, the balance sheet carried USD 4.3 million in cash, enough to continue into the new year, as Silver Viper currently has an excellent track record of discoveries at La Virginia and the new El Rubi zone.

Management and institutional investors own 83% of the shares, leaving only a small free float of 17%. Nearly halved in value since the summer, the Company has a capitalization of only CAD 36 million. It should therefore come as no surprise that after the tax-induced sales, a stronger catch-up movement is starting in December.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read